P. Browne, D. Chandraratna, and C. Angood, Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity, Neurology, vol.83, issue.11, pp.1022-1024, 2014.

. Histoire-de-la, , 2012.

L. G. Dimitrov and B. Turner, What's new in multiple sclerosis?, Br J Gen Pract, vol.64, issue.629, pp.612-613, 2014.

S. Vukusic and C. Confavreux, Histoire naturelle de la sclérose en plaques. /data/revues/07554982/v39i3/S075549820900565X, 2010.

, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, Lancet Lond Engl, vol.352, issue.9139, pp.1498-1504, 1998.

K. P. Johnson, B. R. Brooks, and J. A. Cohen, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, issue.7, pp.1268-1276, 1995.

C. H. Polman, P. W. O'connor, and E. Havrdova, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.899-910, 2006.

K. A. Chamberlain, S. E. Nanescu, K. Psachoulia, and J. K. Huang, Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis, Neuropharmacology, vol.110, pp.633-643, 2016.

J. Renaud, H. Thérien, M. Plouffe, and M. Martinoli, La neuro-inflammation -Dr Jekyll ou Mr Hyde ? médecine/sciences, vol.31, pp.979-988, 2015.

A. Compston and A. Coles, Multiple sclerosis, Lancet Lond Engl, vol.372, issue.9648, pp.1502-1517, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00996686

A. J. Thompson, B. L. Banwell, and F. Barkhof, Namerow NS, Enns N. Visual evoked responses in patients with multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.17, issue.2, pp.829-833, 1972.

D. Vecchio and D. Vecchio, doi:The History of Cerebrospinal Fluid Analysis in Multiple Sclerosis: A Great Development over the Last Centuries 14, NUCLEAR MAGNETIC RESONANCE IMAGING OF THE BRAIN IN MULTIPLE SCLEROSIS. The Lancet, vol.1, 2017.

, , vol.318, pp.1063-1066

C. M. Poser, D. W. Paty, and L. Scheinberg, The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment, Handb Clin Neurol, vol.13, issue.3, pp.173-189, 1983.

M. Sospedra and R. Martin, Immunology of multiple sclerosis, Annu Rev Immunol, vol.23, pp.683-747, 2005.

M. Salou, E. Ngono, A. Garcia, A. Michel, L. Laplaud et al., Immunité adaptative et physiopathologie de la sclérose en plaques, Rev Médecine Interne, vol.34, issue.8, pp.479-486, 2013.

J. M. Gelfand, B. Cree, and S. L. Hauser, Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis, Neurother J Am Soc Exp Neurother, vol.14, issue.4, pp.835-841, 2017.

P. Durozard, A. Maarouf, and C. Boutiere, Efficacy of rituximab in refractory RRMS, Mult Scler Houndmills Basingstoke Engl, vol.25, issue.6, pp.828-836, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02066062

C. A. Dendrou, L. Fugger, and M. A. Friese, Immunopathology of multiple sclerosis, Nat Rev Immunol, vol.15, issue.9, pp.545-558, 2015.

T. A. Yednock, C. Cannon, L. C. Fritz, F. Sanchez-madrid, L. Steinman et al., Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin, Nature, vol.356, issue.6364, pp.63-66, 1992.

E. ;. Masson and . Em-consulte, Physiopathologie de la sclérose en plaques, 2019.

J. E. Merrill, L. J. Ignarro, M. P. Sherman, J. Melinek, and T. E. Lane, Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide, J Immunol Baltim Md, vol.151, issue.4, pp.2132-2141, 1950.

J. Simpson, P. Rezaie, J. Newcombe, M. L. Cuzner, D. Male et al., Expression of the betachemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue, J Neuroimmunol, vol.108, issue.1-2, pp.192-200, 2000.

C. Lubetzki and B. Stankoff, Demyelination in multiple sclerosis, Handb Clin Neurol, vol.122, pp.89-99, 2014.

M. Labalette, S. Bahram, and M. C. Béné, Le complexe majeur d'histocompatibilité humain (HLA). :13. 28. Hollenbach JA, Oksenberg JR. The Immunogenetics of Multiple Sclerosis: A Comprehensive Review, J Autoimmun, vol.64, pp.13-25, 2015.

N. A. Patsopoulos, L. F. Barcellos, and R. Q. Hintzen, Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects, PLoS Genet

, , vol.9, p.1003926

L. Fugger, M. A. Friese, and J. I. Bell, From genes to function: the next challenge to understanding multiple sclerosis, Nat Rev Immunol, vol.9, issue.6, pp.408-417, 2009.

A. Ascherio and M. Munch, Epstein-Barr virus and multiple sclerosis, Epidemiol Camb Mass, vol.11, issue.2, pp.220-224, 2000.

K. L. Munger, L. I. Levin, E. J. O'reilly, K. I. Falk, and A. Ascherio, Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.10, pp.1185-1193, 2011.

M. A. Sospedra and R. Martin, Molecular mimicry in multiple sclerosis, Autoimmunity, vol.39, issue.1, pp.3-8, 2006.

C. H. Hawkes, Smoking is a risk factor for multiple sclerosis: a metanalysis, Mult Scler Houndmills Basingstoke Engl, vol.13, issue.5, pp.610-615, 2007.

J. Salzer, G. Hallmans, M. Nyström, H. Stenlund, G. Wadell et al., Smoking as a risk factor for multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.19, issue.8, pp.1022-1027, 2013.

Y. Schoindre, O. Benveniste, and N. Costedoat-chalumeau, Vitamine D et auto-immunité. /data/revues/07554982/v42i10/S0755498213006817, 2013.

C. Pierrot-deseilligny and J. Souberbielle, Vitamin D and multiple sclerosis: An update, Mult Scler Relat Disord, vol.14, pp.35-45, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01501453

F. Castillo-Álvarez, M. E. Marzo-sola, D. S. Reich, C. F. Lucchinetti, and P. A. Calabresi, Role of intestinal microbiota in the development of multiple sclerosis, Neurol Barc Spain, vol.32, issue.3, pp.169-180, 2017.

M. Debouverie, S. Pittion-vouyovitch, S. Louis, T. Roederer, and F. Guillemin, Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. Mult Scler Houndmills Basingstoke Engl, vol.13, pp.962-967, 2007.

E. Leray, T. Moreau, A. Fromont, and G. Edan, Epidemiology of multiple sclerosis, Rev Neurol
URL : https://hal.archives-ouvertes.fr/hal-01255824

, , vol.172, pp.3-13

F. D. Lublin, S. C. Reingold, and J. A. Cohen, Defining the clinical course of multiple sclerosis, Neurology, vol.83, issue.3, pp.278-286, 2014.

C. Díaz, L. A. Zarco, and D. M. Rivera, Highly active multiple sclerosis: An update, Mult Scler Relat Disord, vol.30, pp.215-224, 2019.

C. Carra-dallière, X. Ayrignac, M. Charif, and P. Labauge, Rebond d'activité inflammatoire et triggers de poussées, POINT SUR, vol.21, p.6, 2018.

I. Meinl, J. Havla, R. Hohlfeld, and T. Kümpfel, Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.24, issue.7, pp.991-994, 2018.

G. Novi, A. Ghezzi, and M. Pizzorno, Dramatic rebounds of MS during pregnancy following fingolimod withdrawal, Neurol Neuroimmunol Neuroinflammation, vol.4, issue.5, p.377, 2017.

P. W. O'connor, A. Goodman, and L. Kappos, Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis, Neurology, vol.76, issue.22, pp.1858-1865, 2011.

L. De-giglio, C. Gasperini, C. Tortorella, M. Trojano, and C. Pozzilli, Natalizumab discontinuation and disease restart in pregnancy: a case series, Acta Neurol Scand, vol.131, issue.5, pp.336-340, 2015.

V. Martinelli, B. Colombo, D. Costa, and G. , Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.11, pp.1506-1508, 2016.

C. Papeix, S. Vukusic, and R. Casey, Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort, Neurol Neuroimmunol Neuroinflammation, vol.3, issue.6, p.297, 2016.

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1452, 1983.

S. Vukusic and C. Confavreux, Sclérose en plaques et grossesse. /data/revues/00353787/01620003/299, 2008.

C. Confavreux, M. Hutchinson, M. M. Hours, P. Cortinovis-tourniaire, and T. Moreau, Rate of Pregnancy-Related Relapse in Multiple Sclerosis, N Engl J Med, vol.339, issue.5, pp.285-291, 1998.

P. Cavalla, V. Rovei, and S. Masera, Fertility in patients with multiple sclerosis: current knowledge and future perspectives, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, vol.27, issue.4, pp.231-239, 2006.

S. Vukusic, M. Hutchinson, and M. Hours, Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse, Brain J Neurol, vol.127, pp.1353-1360, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00427677

M. B. D'hooghe, G. Nagels, and B. Uitdehaag, Long-term effects of childbirth in MS, J Neurol Neurosurg Psychiatry, vol.81, issue.1, pp.38-41, 2010.

L. Pastò, E. Portaccio, and A. Ghezzi, Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study, BMC Neurol, vol.12, p.165, 2012.

K. Hellwig, M. Rockhoff, and S. Herbstritt, Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses, JAMA Neurol, vol.72, issue.10, pp.1132-1138, 2015.

T. D. Griffiths and P. K. Newman, Steroids in multiple sclerosis, J Clin Pharm Ther, vol.19, issue.4, pp.219-222, 1994.

E. M. Martínez-cáceres, M. A. Barrau, L. Brieva, C. Espejo, N. Barberà et al., COPOUSEP : corticoïdes à forte dose par voie orale versus intraveineuse dans le traitement des poussées de sclérose en plaques : un essai randomisé en double insu : résultats du critère majeur d'efficacité à 1 mois. /data/revues/00353787/v170sS1/S0035378714005566, Clin Exp Immunol, vol.127, issue.1, pp.165-171, 2002.

S. Liu, X. Liu, S. Chen, Y. Xiao, and W. Zhuang, Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials, PloS One, vol.12, issue.11, p.188644, 2017.

R. W. Beck, D. L. Chandler, and S. R. Cole, Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses, Ann Neurol, vol.51, issue.4, pp.481-490, 2002.

L. D. Jacobs, D. L. Cookfair, and R. A. Rudick, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, vol.39, issue.3, pp.285-294, 1996.

L. Kappos, M. S. Freedman, and C. H. Polman, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, vol.8, issue.11, pp.987-997, 2009.

D. W. Paty and D. K. Li, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group, Neurology, vol.43, issue.4, pp.662-667, 1993.

P. A. Calabresi, B. C. Kieseier, and D. L. Arnold, Pegylated interferon ?-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, Lancet Neurol, vol.13, issue.7, pp.657-665, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01097451

D. L. Arnold, S. Narayanan, and S. Antel, Neuroprotection with glatiramer acetate: evidence from the PreCISe trial, J Neurol, vol.260, issue.7, pp.1901-1906, 2013.

G. Comi, M. Filippi, and J. S. Wolinsky, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, Ann Neurol, vol.49, issue.3, pp.290-297, 2001.

R. Gold, L. Kappos, and D. L. Arnold, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N Engl J Med, vol.367, issue.12, pp.1098-1107, 2012.

R. J. Fox, D. H. Miller, and J. T. Phillips, Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, N Engl J Med, vol.367, issue.12, pp.1087-1097, 2012.

, Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis | NEJM, 2019.

C. Confavreux, P. O'connor, and G. Comi, Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Neurol, vol.13, issue.3, pp.247-256, 2014.

P. A. Calabresi, E. Radue, and D. Goodin, Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol, vol.13, issue.6, pp.545-556, 2014.

T. P. Leist, G. Comi, and B. Cree, Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol, vol.13, issue.3, pp.257-267, 2014.

H. Hartung, R. Gonsette, and N. König, Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial, Lancet Lond Engl, vol.360, issue.9350, pp.2018-2025, 2002.

S. L. Hauser, A. Bar-or, and G. Comi, Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.376, issue.3, pp.221-234, 2017.

A. J. Coles, C. L. Twyman, and D. L. Arnold, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet Lond Engl, vol.380, issue.9856, pp.61768-61769, 2012.

D. T. Selewski, G. V. Shah, B. M. Segal, P. A. Rajdev, and S. K. Mukherji, Natalizumab (Tysabri), Am J Neuroradiol, vol.31, issue.9, pp.1588-1590, 2010.

R. R. Lobb and M. E. Hemler, The pathophysiologic role of alpha 4 integrins in vivo, J Clin Invest, vol.94, issue.5, 1994.

A. Lupattelli, O. Spigset, and M. J. Twigg, Medication use in pregnancy: a cross-sectional, multinational web-based study, BMJ Open, vol.4, issue.2, p.4365, 2014.

. Médicaments,

. Accessed, , 2019.

, Académie Natl Médecine Une Inst Dans Son Temps, 2009.

D. Evain-brion, P. Berveiller, and S. Gil, Le passage transplacentaire des médicaments, Thérapie, vol.69, issue.1, pp.3-11, 2014.

E. Alsat and D. Evain-brion, Le placenta humain : neuf mois d'une intense activité encore méconnue

. Médecine-thérapeutique-pédiatrie, , vol.1, pp.509-516, 1999.

M. Sandberg-wollheim, E. Alteri, M. S. Moraga, and G. Kornmann, Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.4, pp.423-430, 2011.

P. K. Coyle, S. M. Sinclair, A. E. Scheuerle, J. M. Thorp, J. D. Albano et al., Final results from the Betaseron (interferon ?-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events, Release Dimethyl Fumarate and Pregnancy, vol.4, pp.9-14, 2014.

, Pregnancy Outcome and Teriflunomide Treatment Exposure for Relapsing Remitting Multiple Sclerosis A 4 year follow up (P1.359) | Neurology, Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience, vol.4, pp.93-104, 2015.

G. Karlsson, G. Francis, and G. Koren, Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis, Neurology, vol.82, issue.8, pp.674-680, 2014.

J. T. Yang, H. Rayburn, and R. O. Hynes, Cell adhesion events mediated by ?4 integrins are essential in placental and cardiac development, p.12

A. M. Sheppard, M. D. Onken, G. D. Rosen, P. G. Noakes, and D. C. Dean, Expanding roles for alpha 4 integrin and its ligands in development, Cell Adhes Commun, vol.2, issue.1, pp.27-43, 1994.

G. Tarone, E. Hirsch, and M. Brancaccio, Integrin function and regulation in development, Int J Dev Biol, vol.44, issue.6, pp.725-731, 2000.

S. Friend, S. Richman, G. Bloomgren, L. M. Cristiano, and M. Wenten, Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study, BMC Neurol, vol.16, issue.1, p.150, 2016.

K. Hellwig, A. Haghikia, and R. Gold, Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.8, pp.958-963, 2011.

E. Portaccio, P. Annovazzi, and A. Ghezzi, Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks, Neurology, vol.90, issue.10, pp.823-831, 2018.

A. Haghikia, A. Langer-gould, and G. Rellensmann, Natalizumab use during the third trimester of pregnancy, JAMA Neurol, vol.71, issue.7, pp.891-895, 2014.

U. Mahadevan, C. F. Martin, and R. S. Sandler, 865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy, Gastroenterology, vol.142, issue.5, pp.60561-60568, 2012.

N. G. Wehner, G. Shopp, S. Oneda, and J. Clarke, Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor, Birth Defects Res B Dev Reprod Toxicol, vol.86, issue.2, pp.117-130, 2009.

N. G. Wehner, G. Shopp, M. S. Rocca, and J. Clarke, Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs, Birth Defects Res B Dev Reprod Toxicol, vol.86, issue.2, pp.98-107, 2009.

S. Friend, S. Richman, G. Bloomgren, L. M. Cristiano, and M. Wenten, Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study, BMC Neurol, vol.16, issue.1, p.150, 2016.

N. Ebrahimi, S. Herbstritt, R. Gold, L. Amezcua, G. Koren et al., Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study, Mult Scler Houndmills Basingstoke Engl, vol.21, issue.2, pp.198-205, 2015.

J. Fagius and J. Burman, Normal outcome of pregnancy with ongoing treatment with natalizumab, Acta Neurol Scand, vol.129, issue.6, pp.27-29, 2014.

K. Hellwig, A. Haghikia, and R. Gold, Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.8, pp.958-963, 2011.

I. A. Hoevenaren, L. C. De-vries, R. Rijnders, F. K. Lotgering, E. Portaccio et al., Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks, Acta Neurol Scand, vol.123, issue.6, pp.823-831, 2011.

H. Schneider, C. E. Weber, K. Hellwig, H. Schroten, and T. Tenenbaum, Natalizumab treatment during pregnancy -effects on the neonatal immune system, Acta Neurol Scand, vol.127, issue.1, pp.1-4, 2013.

A. Peng, X. Qiu, and L. Zhang, Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review, J Neurol Sci, vol.396, pp.202-205, 2019.

J. Frau, M. P. Sormani, and A. Signori, Clinical activity after fingolimod cessation: disease reactivation or rebound?, Eur J Neurol, vol.25, issue.10, pp.1270-1275, 2018.

P. S. Sorensen, N. Koch-henriksen, T. Petersen, M. Ravnborg, A. Oturai et al., Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients, J Neurol, vol.261, issue.6, pp.1170-1177, 2014.

A. P. Sempere, L. Berenguer-ruiz, and E. Feliu-rey, Rebound of disease activity during pregnancy after withdrawal of fingolimod, Eur J Neurol, vol.20, issue.8, pp.109-110, 2013.

E. Portaccio, L. Moiola, and V. Martinelli, Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks, Neurology, vol.90, issue.10, pp.832-839, 2018.

S. Vukusic, M. Hutchinson, and M. Hours, Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse, Brain J Neurol, vol.127, pp.1353-1360, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00427677

G. Koren and A. Ornoy, The role of the placenta in drug transport and fetal drug exposure, Expert Rev Clin Pharmacol, vol.11, issue.4, pp.373-385, 2018.

A. Correa, J. D. Cragan, and J. E. Kucik, Reporting birth defects surveillance data 1968-2003, Birt Defects Res A Clin Mol Teratol, vol.79, issue.2, pp.65-186, 2007.

F. Vendittelli, O. Rivière, and C. Crenn-hébert, Audipog perinatal network. Part 1: principal perinatal health indicators, 2004.

, Gynecol Obstet Fertil, vol.36, issue.11, pp.1091-1100, 2008.

A. Haghikia, A. Langer-gould, and G. Rellensmann, Natalizumab use during the third trimester of pregnancy, JAMA Neurol, vol.71, issue.7, pp.891-895, 2014.

L. Guilloton, A. Pegat, J. Defrance, L. Quesnel, G. Barral et al., Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy, J Gynecol Obstet Hum Reprod, vol.46, issue.3, pp.301-302, 2017.

A. Delabaere, C. Huchon, and X. Deffieux,

, J Gynecol Obstet Biol Reprod, vol.43, issue.10, pp.764-775, 2014.

F. Blohm, B. Fridén, and I. Milsom, Dimesse dagli istituti di cura per aborto spontaneo e Indagine rapida sulle donne dimesse per aborto spontaneo, BJOG Int J Obstet Gynaecol, vol.115, issue.2, pp.176-182, 2008.

J. Lévesque, Y. Takamatsu, S. K. Nilsson, D. N. Haylock, and P. J. Simmons, Rôle des intégrines et sélectines dans le développement et les régulations du système hématopoïétique, Hématologie, vol.7, issue.2, pp.99-109, 2001.